---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-001774"
form_type: "8-K"
ticker: "CHRN"
cik: "0001549084"
company_name: "EKSO BIONICS HOLDINGS, INC."
filed_at: "2026-01-22T23:59:59+00:00"
generated_at: "2026-05-16T08:46:21.276170+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Ekso Bionics raises ~$5.3M net via private placement of Series B convertible preferred and warrants

## Summary
- Issued 5,852 shares of Series B Convertible Preferred Stock (stated value $1,000/share) and warrants for 355,960 shares.
- Conversion price and warrant exercise price set at $8.22 per share of common stock; 6-month lock-up on transfers.
- Net proceeds of ~$5.3M after ~$0.4M placement agent fees; intended for working capital and general corporate purposes.
- Filed Certificate of Designation for Series B Preferred with Nevada Secretary of State on January 22, 2026.
- Lake Street Capital Markets acted as exclusive placement agent; received a 6% cash fee and a warrant for 14,238 shares.

## SEC filing metadata
- accession: 0001437749-26-001774
- form_type: 8-K
- ticker: CHRN
- cik: 0001549084
- company_name: EKSO BIONICS HOLDINGS, INC.
- filed_at: 2026-01-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.02, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1549084/000143774926001774/0001437749-26-001774-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1549084/000143774926001774/ekso20260122_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-001774
- JSON: https://secwatch.observer/filing/0001437749-26-001774.json
- Plain text: https://secwatch.observer/filing/0001437749-26-001774.txt

## Source-grounded claims
- claim_id: 74331fd7384e43f739c2b4cd7238985c4a24b745
  claim: EKSO BIONICS HOLDINGS, INC.: Filed a Certificate of Designation for Series B Convertible Preferred Stock to the Restated Articles of Incorporation (effective 2026-01-22).
  evidence_excerpt: In connection with the Private Placement, on January 22, 2026, the Company filed a Certificate of Designation of the Powers, Preferences and Relative, Participating, Option and Other Restrictions of the Series B Preferred Stock (the “Certificate of Designation”) to the Company’s Restated Articles of Incorporation with the Secretary of State of the State of Nevada.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1549084/000143774926001774/0001437749-26-001774-index.htm
- claim_id: 9750319a22d7d94858bae36862ad1e646ed98232
  claim: EKSO BIONICS HOLDINGS, INC. entered into Purchase Agreements with certain institutional and accredited investors valued at approximately $5.3 million (effective 2026-01-20).
  evidence_excerpt: On January 20, 2026, Ekso Bionics Holdings, Inc. (the “Company”) entered into securities purchase agreements (collectively, the “Purchase Agreements”) with certain institutional and accredited investors (the “Purchasers”), pursuant to which the Company agreed to issue and sell, in a private placement (the “Private Placement”), (i) an aggregate of 5,852 shares of the Company’s newly designated Series B Convertible Preferred Stock, with a par value $0.001 per share and stated value (the “Stated Value”) of $1,000 per share (the “Series B Preferred Stock”) convertible into an aggregate of 711,922 shares (the “Conversion Shares”) of common stock of the Company, par value $0.001 per share (the “Common Stock”) at a conversion price of $8.22 per share, subject to certain customary adjustments, and (ii) warrants (the “Warrants”) to purchase up to an aggregate of 355,960 shares of Common Stock at an exercise price of $8.22 per share of Common Stock.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1549084/000143774926001774/0001437749-26-001774-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.